In terms of infection, SGLT-2 inhibitors did not significantly increase the risk of overall urinary tract infection (UTI), compared to the control group, with a RR of 0.51 (95% CI 0.25, 1.01; p = 0.05) with a significant heterogeneity (I2 = 79%) across 7 studies17–23 as shown inFigure 5A. The gene discussed is SLC5A2; the disease is bacterial urinary tract infection.